Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
Mepolizumab significantly reduces exacerbations in patients with severe eosinophilic asthma. The early identification of patients likely to receive long-term benefit from treatment could ensure effective resource allocation.
To assess potential continuation rules for mepolizumab in addition to initiation criteria defined as 2 or more exacerbations in the previous year and blood eosinophil counts of 150 cells/mL or more at initiation or 300 cel...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 865.5KB)
- Publisher copy:
- Elsevier Publisher's website
- Journal of Allergy and Clinical Immunology: In Practice Journal website
- Publication date:
- Acceptance date:
- Source identifiers:
- Copyright holder:
- Pavord et al
- Copyright date:
- © 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma and Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
If you are the owner of this record, you can report an update to it here: Report update to this record